Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 With reference to above subject, please find enclosed News Release of our company Titled 'Suven Life sciences announces Phase 3 Clinical Trial of SUVN-502 (Masupirdine), a 5-HT6 antagonist for treatment of Agitation and aggression in Alzheimer's type dementias' In this connection, in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended and in terms of the Code of Conduct of the Company for prevention of Insider Trading, the "Trading Window" for dealing in the securities of the Company shall remain closed for the Directors, Promoters, other Designated Persons, and immediate relatives of Designated Persons covered under the said code read with the SEBI Regulations, from 17th August 2021 to 18th August 2021 (both days inclusive). Please further note that Trading window will be opened from 19th August, 2021. You are requested to take this notice on your record.
16-08-2021
Bigul

Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed the copies of the newspaper advertisement regarding Un-audited Financial Results of the Company for quarter ended 30th June, 2021. The advertisements are as appeared on 10th August, 2021 in Business Standard and Nava Telangana (Telugu). The above information will also be hosted on the website of the Company at: http://www.suven.com/newspaperads.aspx This is for your information and record.
10-08-2021
Bigul

Suven Life Sciences Ltd - 530239 - Statement Of Deviation(S) Or Variation(S) For The Quarter Ended 30Th June, 2021 Under Regulation 32 Of SEBI (LODR) Regulations, 2015.

 With reference to the above subject, please find enclosed statement confirming that there were no deviation(s) or variation(s) in the use of proceeds, from the objects for which funds were raised through the preferential issue made by the Company, for the quarter ended 30th June, 2021. We request you to take this on your record.
09-08-2021
Bigul

SUVEN LIFE SCIENCES LTD. - 530239 - Board Meeting Outcome for Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended 30Th June, 2021.

 With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 09th August, 2021, has taken on record and approved the Un-audited Standalone and Consolidated Financial Results of the Company under Ind AS along with review reports of the Statutory Auditors for the quarter ended 30th June, 2021. We are enclosing herewith the following documents: a) Un-audited Standalone and Consolidated Financial Results under Ind AS for the quarter ended 09th August, 2021. b) Limited Review Reports of Statutory Auditors of the Company on the financial results as mentioned above and c) A copy of the News Release of our company Update on patents during this period can be viewed at: http://suven.com/Patentupdates.aspx We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:30 P.M.
09-08-2021
Bigul

Suven Life Sciences Ltd - 530239 - Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended 30Th June, 2021

 With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 09th August, 2021, has taken on record and approved the Un-audited Standalone and Consolidated Financial Results of the Company under Ind AS along with review reports of the Statutory Auditors for the quarter ended 30th June, 2021. We are enclosing herewith the following documents: a) Un-audited Standalone and Consolidated Financial Results under Ind AS for the quarter ended 09th August, 2021. b) Limited Review Reports of Statutory Auditors of the Company on the financial results as mentioned above and c) A copy of the News Release of our company Update on patents during this period can be viewed at: http://suven.com/Patentupdates.aspx We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:30 P.M.
09-08-2021
Bigul

Suven Life Sciences Ltd - 530239 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

 Suven Life Sciences Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here
06-08-2021
Bigul

SUVEN LIFE SCIENCES LTD. - 530239 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

 This is with reference to our earlier letter dated 12th July, 2021 regarding the 32nd Annual General Meeting (AGM) of the Company held today i.e. Friday, 06th August, 2021 and the business mentioned in the Notice dated 04th May, 2021 was transacted. In this regard, please find enclosed the following: 1. Summary of proceedings as required under the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as Annexure - I 2. Voting Results as required under Regulation 44 of the SESI (Listing Obligations and Disclosure Requirements) Regulations 2015 as Annexure- II 3. The Report of Scrutinizer on remote e-voting and voting at AGM (by electronic means) as Annexure- III We request you to take the documents on your record.
06-08-2021
Bigul

SUVEN LIFE SCIENCES LTD. - 530239 - Shareholder Meeting / Postal Ballot-Outcome of AGM

 This is with reference to our earlier letter dated 12th July, 2021 regarding the 32nd Annual General Meeting (AGM) of the Company held today i.e. Friday, 06th August, 2021 and the business mentioned in the Notice dated 04th May, 2021 was transacted. In this regard, please find enclosed the following: 1. Summary of proceedings as required under the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as Annexure - I 2. Voting Results as required under Regulation 44 of the SESI (Listing Obligations and Disclosure Requirements) Regulations 2015 as Annexure- II 3. The Report of Scrutinizer on remote e-voting and voting at AGM (by electronic means) as Annexure- III We request you to take the documents on your record.
06-08-2021
Bigul

SUVEN LIFE SCIENCES LTD. - 530239 - Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Be Held On Monday, The 09Th August, 2021

 SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2021 ,inter alia, to consider and approve The Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the quarter ended 30th June, 2021 and related matters.
02-08-2021
Bigul

SUVEN LIFE SCIENCES LTD. - 530239 - Statement Of Investor Complaints For The Quarter Ended June 2021

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 010100 Name of the Signatory :- Shrenik SoniDesignation :- Company Secretary and Compliance Officer
20-07-2021
Next Page
Close

Let's Open Free Demat Account